摘要
目的:比较培跺普利、福辛普利对心力衰竭患者的生存质量和炎性细胞因子的影响。探讨两药治疗心力衰竭的疗效与安全性。方法:87例心衰患者随机分为培跺普利组、福辛普利组和对照组。治疗前、后测定血清肿瘤坏死因子α(TNFα)、白介素 6(IL-6)、白介素1β(IL-1β)、血肌酐(Cr)、尿素氮(BUN)、血钾(K^+)、每搏量(SV)、心输血量(CO)、左室射血分数(LVEF)。同时进行6分钟步行试验(6MWT)、明尼苏达心衰问卷评分(ML WHF),记录用药过程中的不良反应。结果:治疗4周后,两组患者IL-6水平显著下降(P<0.01),福辛普利组TNFα水平下降(P<0.05)。两组患者SV、CO、LVEF水平均上升(P<0.01);6MWT显著增加(P<0.001);ML WHF明显下降(P<0.001);BUN、SCr、K^+无统计学变化。结论:培哚普利和福辛普利都能有效治疗心衰,减少炎性细胞因子,改善生活质量。福辛普利在降低TNFα上更有优势。
Objective: This study was to compare perindopril and fosinopril in improvement of quality of life and decrease of proinflammatory cytokines in patients with congestive heart failure (CHF), evaluate the therapeutic efficiency and safety of the two drugs. Methods: The 87 patients with CHF were randomized divided into perindopril group (n = 30), fosinopril group (n = 29) and control group (n = 28). Serum TNFα、 IL -6、 IL-1β、 Cr、 BUN、 K+、 SV、 CO、 LVEF were measured before treatment and after treatment 4 weeks. 6MWT, MLWHF were examined in same time. Results: After treatment 4 weeks, IL -6 level and MLWHF of two groups decreased (P<0. 01 all). SV, CO, LVEF and 6 MWT of two groups increased (P<0. 01-<0. 001). TNF### level decreased (P<0. 05) in fosinopril group. Conclusion: Both perindopril and fosinopril can decrease proinflammatory cytokine and improve the quality of life in CHF patients. In some parameters, fosinopril have the dominance (example decrease TNFα).
出处
《心血管康复医学杂志》
CAS
2003年第5期427-429,共3页
Chinese Journal of Cardiovascular Rehabilitation Medicine
